XFOR insiders were on both sides of the trade this year. Buys came to roughly $250,000 (one buyer), sales to $463,000 (three sellers).
Biggest single buyer: Craig Adam R, Chair, with roughly $250,000.
On the institutional side, 88 funds reported holding XFOR at the end of Q2 2026, and more funds bought than sold. Zooming out by quarter: 2 quarters in a row of net selling by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | KIRSKE DAVID | CFO | Sell | 11,767 | $2.86 | $34K | SEC |
| Aug 13, 2026 | Volpone John | President | Sell | 24,576 | $4.44 | $109K | SEC |
| Aug 13, 2026 | Craig Adam R | Chair | Sell | 47,436 | $4.44 | $211K | SEC |
| Jul 1, 2026 | KIRSKE DAVID | CFO | Sell | 8,543 | $4.26 | $36K | SEC |
| May 13, 2026 | KIRSKE DAVID | CFO | Sell | 16,961 | $4.29 | $73K | SEC |
| Oct 27, 2025 | Craig Adam R | Chair | Buy | 86,206 | $2.90 | $250K | SEC |
| May 20, 2025 | Baldry Mark | Executive Officer | Buy | 1,032 | $2.48 | $3K | SEC |
| Feb 14, 2025 | Baldry Mark | Executive Officer | Buy | 21,646 | $0.68 | $15K | SEC |
| Feb 14, 2025 | Baldry Mark | Executive Officer | Buy | 13,404 | $0.34 | $5K | SEC |
| Jan 27, 2025 | Ragan Paula | CEO | Sell | 76,473 | $0.45 | $34K | SEC |
| Jan 27, 2025 | Mostafa Adam S. | CFO | Sell | 74,773 | $0.45 | $34K | SEC |
| Jan 27, 2025 | Baldry Mark | Executive Officer | Sell | 29,159 | $0.45 | $13K | SEC |
| Jan 27, 2025 | DiBiase Mary | COO | Sell | 22,258 | $0.45 | $10K | SEC |
| Jan 27, 2025 | Arbet-Engels Christophe | Executive Officer | Sell | 11,624 | $0.45 | $5K | SEC |
| Nov 19, 2024 | Ragan Paula | CEO | Sell | 31,897 | $0.39 | $12K | SEC |
In the last 12 months X4 Pharmaceuticals, Inc insiders made open-market purchases worth about $250,000 and sales worth about $463,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in XFOR was filed on 2026-10-05.
88 investment managers reported holding XFOR in SEC Form 13F filings for Q2 2026.
No congressional trades in XFOR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).